Cancer claims the lives of over 500,000 Americans a year. Unfortunately, the majority of current cancer therapies are only designed to reduce the growth of primary tumors - an approach that does not directly treat tumor spread or metastatic progression. As a result, despite an ever-growing arsenal of cancer therapeutics, the annual mortality rates from cancer have remained virtually unchanged over the past half-century. The lack of effective therapeutics against the progression of the majority of cancers results, in turn, from an inadequate understanding of the biological pathways that drive the growth of metastatic disease.
This year over 8 million people will die from cancer globally, most as a result of metastatic disease stemming from ineffective available therapies and drug resistance. We aim to save lives by developing novel drugs with robust and persistent efficacy in cancer patients who lack effective therapies.- Dr. Masoud Tavazoie (co-founder) -